STADE-HF (sST2 as a Help for Management of HF): A Pilot Study
ESC Heart Failure2020Vol. 7(2), pp. 774–778
Citations Over Time
Fabien Huet, Jean Nicoleau, Anne‐Marie Dupuy, Corentin Curinier, Cyril Breuker, Audrey Castet‐Nicolas, Manuela Lotierzo, Eran Kalmanovich, L. Zerkowski, Mariama Akodad, Jérôme Adda, Audrey Agullo, Florence Leclercq, Jean‐Luc Pasquié, Pascal Battistella, C. Roubille, Pierre Fesler, Grégoire Mercier, Guillaume Bourel, Jean‐Paul Cristol, François Roubille
Abstract
Soluble suppression of tumorigenicity 2-guided therapy over a short period of time does not reduce readmissions. However, sST2 was clearly associated with duration of hospitalization, and the decrease in sST2 was associated with decreased rehospitalizations. Long-term outcome using sST2-guided therapy deserves further investigations.
Related Papers
- → Isolated bacterial infection without decompensation has no impact on survival of compensated patients with cirrhosis(2021)12 cited
- → Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis(2024)3 cited
- → Lipid levels in patients with decompensation and mortality after an index hospitalization for acute heart failure(2021)
- → Clinical and prognostic characterization of the patterns of decompensation of liver cirrhosis(2022)
- → Reply to: Correspondence on “A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis”(2024)